Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Expansion Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: http://www.expansionrx.com
Year Founded: 2016
Status: Private
BioCentury | Dec 7, 2022
Management Tracks
Bill Meury to lead Karuna
Plus: Moore to head Roche Diagnostics North America division, and updates from Agios, Verge, LifeMine and more
BioCentury | Nov 30, 2022
Data Byte
Rgenta’s A round adds fuel to RNA-targeting small molecule space
$52M round led by AstraZeneca’s joint fund with China International Capital
BioCentury | Sep 23, 2022
Discovery & Translation
PROTAC logic continues to evolve
New publications highlight bispecific antibody degraders as a way to eliminate a cell surface target
BioCentury | Mar 3, 2022
Emerging Company Profile
NextRNA: small molecules take on lncRNA-protein interactions
With $56M, the Dana-Farber spinout is developing RNA- and protein-targeting therapies for cancer and immunology
BioCentury | Feb 5, 2022
Discovery & Translation
Wave’s oligos enhance tissue exposure; plus Rosenberg, Disney and more
BioCentury’s roundup of translational news
BioCentury | Jan 25, 2022
Management Tracks
Braunstein now CMO at Idorsia
Plus Kush, Haddach join RayzeBio and updates from Coherus, InterVenn, AsherBio and more
BioCentury | Jan 12, 2022
Deals
Amgen, Arrakis taking the logic of PROTACs to RNA degraders
Michael Gilman-led biotech gets $75M up front in expandable five-target deal uniting platforms
BioCentury | Oct 29, 2021
Discovery & Translation
Omics-based target identification in UK Biobank and COVID-19 cohorts
Plus: technologies from Harvard, Texas A&M, Disney lab and more
BioCentury | Sep 30, 2021
Product Development
Sept. 29 Quick Takes: Mirum wins first approval for rare liver disease
Approval for AbbVie’s migraine therapy, Sanofi’s mRNA plans, venture money for Expansion, Kytopen raise
BioCentury | Aug 20, 2021
Product Development
The TAC universe grows beyond PROTACs
Inducing autophagy is becoming a popular strategy as targeting chimeras extend beyond protein degradation
Items per page:
1 - 10 of 44